

C

	Days post intracranial cell implantation								
	10					34			
non-targeted	100,	100,	100,	100,	100,	45.36823	29.44786	1074.673	1124.075
RGD4C/AAVP <i>Grp78-HSVtk</i>	100,	100,	100,	100,	100,	180.6431	54.78537	140.1765	42.87887
TMZ	100,	100,	100,	100,	100,	293.3208	15.71775	2.491297	576.4139
RGD4C/AAVP <i>Grp78-HSVtk +TMZ</i>	100,	100,	100,	100,	100,	3.238107	44.48055	2.91391	13.31329
									2.444983

E

	Days post intracranial cell implantation									
	10					34				
non-targeted	17.9	18.8	18.3	17.7	19.6	20.6	15.8	20.3		16.5
RGD4C/AAVP <i>Grp78-HSVtk</i>	19.3	18.1	18.1	17.4	19.4	18.9		19.8	18.5	18.3
TMZ	18.2	19.4	17.5	19.7	20.5	20.8	19.4	20.1	18.8	16.8
RGD4C/AAVP <i>Grp78-HSVtk +TMZ</i>	18.7	19.1	19.1	19.8	17.6	20.8	20.9	21.3	20.2	20.9
										18.2
										20.5

Figure 9- RGD4C/AAVP-*Grp78-HSVtk* plus GCV gene therapy and combination with TMZ against orthotopic murine GL261 GBM